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Although familial hypertrophic cardiomyopathy (FHC) is characterized as cardiac disease
in the absence of overt stressors, disease penetrance, and pathological progression
largely depend on modifying factors. Accordingly, pressure overload by transverse aortic
constriction (TAC) was induced in 2-month-old, male mice with and without a FHC (R403Q)
mutation in α-myosin heavy chain. A significantly greater number of FHC mice (n = 8)
than wild-type (WT) mice (n = 5) died during the 9-week study period. TAC induced
a significant increase in cardiac mass whether measured at 2 or 9 weeks post-TAC
in both WT and FHC mice, albeit to a different extent. However, the temporal and
morphological trajectory of ventricular remodeling was impacted by the FHC transgene.
Both WT and FHC hearts responded to TAC with an early (2 weeks post-TAC) and
significant augmentation of the relative wall thickness (RWT) indicative of concentric
hypertrophy. By 9 weeks post-TAC, RWT decreased in WT hearts (eccentric hypertrophy)
but remained elevated in FHC hearts. WT hearts following TAC demonstrated enhanced
cardiac function as measured by the end-systolic pressure-volume relationship, pre-load
recruitable stroke work (PRSW), and myocardial relaxation indicative of compensatory
hypertrophy. Similarly, TAC induced differential histological and cellular remodeling;
TAC reduced expression of the sarcoplasmic reticulum Ca2+-ATPase (2a) (SERCA2a; 2
and 9 weeks) and phospholamban (PLN; 2 weeks) but increased PLN phosphorylation
(2 weeks) and β-myosin heavy chain (β-MyHC; 9 weeks) in WT hearts. FHC-TAC hearts
showed increased β-MyHC (2 and 9 weeks) and a late (9 weeks) decrease in PLN
expression concomitant with a significant increase in PLN phosphorylation. We conclude
that FHC hearts respond to TAC induced pressure overload with increased premature
death, severe concentric hypertrophy, and a differential ability to undergo morphological,
functional, or cellular remodeling compared to WT hearts.
Keywords: pressure overload, cardiac hypertrophy, concentric hypertrophy, remodeling, myocardial relaxation,
familial hypertrophic cardiomyopathy
INTRODUCTION
Familial hypertrophic cardiomyopathy (FHC) is clinically het-
erogeneous; some individuals experience limited or no clinical
symptoms while subgroups of patients develop severe deteriora-
tion of cardiac function and symptoms of congestive heart failure
(CHF; Maron, 2002). The clinical diagnosis of FHC is one of
exclusion, hypertrophy in the absence of an overt cardiac dis-
ease etiology. Consequently, identification of FHC is based on the
presence of left ventricular hypertrophy (LVH) plus a mutation
in a gene typically encoding sarcomeric proteins (Bonne et al.,
1998; Towbin, 2000; Marian and Roberts, 2001). Yet, the severity
of these underlying abnormalities especially LV geometry corre-
lates with the risk for sudden cardiac death (Assayag et al., 1997).
Consequently, phenotypic expression of FHC largely depends on
the interaction of the specific mutation and modifying factors
such as genetics, lifestyle, environment, and other co-existing
diseases (Lechin et al., 1995; Bonne et al., 1998; Osterop et al.,
1998). For example, approximately half of patients that harbor
a missense mutation at residue 403 (R403Q) of β-myosin heavy
chain (β-MyHC) die by age 45 from sudden cardiac death or CHF
(Geisterfer-Lowrance et al., 1990; Epstein et al., 1992) whereas
others experience much milder symptoms. Accordingly, identify-
ing underlying etiologies responsible for the clinical heterogeneity
of FHC becomes tantamount to initiating an appropriate treat-
ment strategy. Therefore, it is critical to identify the cellular and
molecular pathology resulting from the interaction of FHC and
these modifying factors.
Arterial hypertension (high-blood pressure) results in cardiac
pressure overload coupled with LVH and is the most common
medical problem in the US (Collins et al., 1990; Kannel, 1996;
Ong et al., 2007). Much like LVH due to FHC, a critical predictor
of clinical prognosis is the geometric pattern of LVH (Devereux
et al., 1994). Considering the clear variability in the patterning of
LVH geometry in the clinical population, it is likely that there is a
significant inheritable component. In support of this contention,
C57BL/6J (B6) and 129S1/SvImJ subjected to pressure overload
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display distinct patterns of LVH illustrating the differential sus-
ceptibility based solely on genetic background (Barrick et al.,
2007).
Given the prominence of hypertension, it has been suggested
that a significant number of patients with unidentified FHC
have hypertension (20%), contributing to its variable penetrance
(Vinereanu et al., 2001; Ortlepp et al., 2002). Interestingly, when
this ismodeled inmice with an FHC (Arg403Gln) mutation in the
native α-cardiac myosin heavy chain (MHC) gene (αMHC403/+),
the response to pressure overload, not surprisingly, depends on
genetic background. Following pressure overload, αMHC403/+
mice on the 129SvEv background show no significant differences
from wild-type (WT) controls whereas αMHC403/+ mice on the
outbred Black Swiss (BS) background show worsening LV geom-
etry, mass, and function compared toWT controls (Schmitt et al.,
2003). This suggests that even in the context of an inheritable
FHC mutation, genetic background plays a prominent role in the
phenotypic manifestation of this disease.
Because FHC symptoms often develop progressively over time
during the development of the disease, the purpose of this study
is 2-fold: (1) to further investigate the impact of pressure overload
on FHC disease pathogenesis using an alternative FHC mouse
model harboring the same mutation (R403Q) but on the C57Bl6
background, and (2) to investigate the temporal impact of pres-
sure overload on the early course of FHC disease pathogenesis.
Because the FHC mice in this study develop early clinical signs
of FHC (Vikstrom et al., 1996), we hypothesized that FHC mice
will respond to pressure overload with worsening cardiac pathol-
ogy more similar to the αMHC403/+ mice on the BS background.
In this study, we induced gradual (progressive) pressure over-
load in WT and FHC mice by applying a loose band to the
transverse aorta of young mice (2 months of age) and allow-
ing them to mature concurrently with increasing afterload. We
subsequently examined 2 separate experimental groups at 2 and
9 weeks post-transverse aortic constriction (TAC) for cardiac
function, ventricular morphology, and cellular remodeling. Here,
we show that WT and FHC mice develop significant cardiac
hypertrophy in response to pressure overload but that FHC mice
show signs of worsening pathology through earlier pathologi-
cal onset, premature death, severe concentric hypertrophy, and
attenuated ability to adapt at the functional and cellular level.
We conclude that co-existing pressure overload and genetic back-
ground play a modifying role in the early course of FHC disease
pathogenesis.
MATERIALS AND METHODS
ANIMAL MODELS
The experimental murine model has been detailed previously and
consisted of male mice heterozygous for the mutant α-myosin
transgene (Vikstrom et al., 1996). The transgene coding region
contains a point mutation, R403Q, and a deletion of 59 amino
acids in the actin-binding site bridged by the addition of 9 non-
myosin amino acids. WT littermates were used as controls for the
FHC mice. All experiments were performed using protocols that
adhered to guidelines and approved by the Institutional Animal
Care andUse Committee at the University of Arizona, and to 2011
NIH guidelines for care and use of laboratory animals.
TRANSVERSE AORTIC CONSTRICTION (TAC)
To determine the temporal impact of TAC on cardiac func-
tion, ventricular morphology, and cellular remodeling, separate
experimental groups of mice were analyzed 2 and 9 weeks post-
TAC. Furthermore, because male FHCmice develop clinical signs
of pathology [myocyte hypertrophy and disarray and expres-
sion of fetal genes (Vikstrom et al., 1996)] by 4 months of age,
TAC surgery was performed at 2 months of age, prior to overt
pathology. Mice were anesthetized by intraperitoneal injection of
Avertin (2,2,2 Tribromoethanol dissolved in 2-methyl-2-butanol,
0.5 g/kg, Sigma). The animals were placed in a supine position,
and the chest was shaved using a chemical hair remover. The aor-
tic arch was exposed through the 1st intercostals. A 6-0 nylon
suture was placed between the brachiocephalic trunk and the left
common carotid artery. A blunted 26-gauge needle was placed
against the aorta, and the aorta was tightened along with the
needle. We chose to use a 26-gauge needle, because a previ-
ous study had shown that aortic banding to a 27-gauge stenosis
induced moderate hypertrophy without clinical signs of decom-
pensated hypertrophy at 5 weeks after aortic banding (Hill et al.,
2000). By using the bigger size of needle, we intended to produce
even more moderate and gradual hypertrophic responses, which
we believe is more clinically relevant. The needle was removed
and the chest was closed. In sham-operated mice, the aorta was
isolated but not tied. The mice were allowed to recover on a
temperature-controlled heating pad until fully recovered.
ECHOCARDIOGRAPHY
Two and 9 weeks post-TAC, echocardiography was carried out
to non-invasively examine morphological and functional changes
associated with pressure overload by TAC. Transthoracic echocar-
diography was performed using a Visual Sonics Vevo 770 high-
resolution imaging system (Visual Sonics, Toronto, ON, Canada).
A 25-MHz transducer was used. The chests of animals were
shaved with a chemical hair remover. Esthesia was maintained
by 1% isoflurane with oxygen. Body temperature was maintained
using a heated platform. Respiratory rates and electrocardiograms
were monitored throughout the study.
Two-dimensional M-mode echocardiographic images were
obtained from the parasternal short-axis views at the level of the
mid-ventricles. Cardiac chamber dimensions and the left ventric-
ular wall thickness were measured. Interventricular septum (IVS),
left ventricular posterior wall thickness (LVPWT), and internal
dimension (LVIDd) were measured from the M-mode images.
Relative wall thickness (RWT) [(LVPWT/LVIDd) × 2] was cal-
culated from the M-mode measurements. Diastolic function was
assessed by conventional pulsed-wave Doppler analysis of mitral
valve inflow patterns from the apical four chamber views. Data
was analyzed off-line using Vevo 770 analytic software. The data
were obtained in triplicate and averaged.
HEMODYNAMICS ANDMEASUREMENTS OF PRESSURE-VOLUME
LOOP RELATIONSHIPS
In vivo hemodynamics and pressure-volume loop relationships
were studied. Anesthesia was maintained by an intraperitoneal
injection of avertin (0.5 g/kg). Endotracheal intubation was per-
formed. Animals were ventilated (145 breaths/minute and 0.2ml
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tidal volume). A closed chest approach was utilized. A 1.4-French
pressure-volume catheter (Scisense, London, ON, Canada) was
inserted into the left ventricle via catheterization of the right
carotid artery. The position of the catheter was carefully adjusted
until stable pressure-volume loops were obtained. The catheter
was connected to a signal processor (Scisense, London, ON,
Canada). Data were obtained digitally using iWorx data acqui-
sition/analysis system (iWorx Systems, Dover, NH). Tracings of
left ventricular pressure and volume were collected at a sam-
pling rate of 1000Hz. The volume was calibrated in each mouse
by the calculation of parallel conductance. Parallel conductance
is a measure of the contribution of the ventricular wall to the
volume signal and is determined by the time-varying electrical
conductance (Porterfield et al., 2009). The parallel conductance
measured was subtracted from the volume signal to yield an
absolute volume.
The end-systolic and end-diastolic pressure-volume relation-
ships were studied by a transient inferior vena cava (IVC) occlu-
sion. Briefly, the abdomen was opened, and the IVC located
between liver and diaphragmwas identified. The transient venous
occlusion was carried out by pinching-off the vena cava using
a pair of plastic forceps. Immediately after measurements of
pressure-volume loops, mice were killed by cervical dislocation.
The heart was removed and cut into 2 halves. One half was
fixed with phosphate-buffered paraformaldehyde (4%) overnight
(4◦C) and processed for histological analysis. The other half was
snap-frozen with liquid N2 and stored (−80◦C) for biochemical
analysis.
FUNCTIONAL PARAMETERS
The following parameters were recorded and analyzed: heart
rate (HR), LV end systolic and diastolic pressure (ESP and
EDP, respectively), end systolic and diastolic volume (ESV and
EDV, respectively), the maximal rates of LV pressure increase
and decrease (dp/dtmax and dp/dtmin), and time constant
of LV pressure decay (tau). The hemodynamic data at base-
line were measured for 3 s immediately before the induction
of a transient IVC occlusion and averaged. Left ventricular
pressure-volume relations were evaluated from pressure-volume
loops recorded during transient occlusion of the IVC. Pre-load
recruitable stroke work (PRSW), end-systolic pressure-volume
relationship (ESPVR) and the slope (Ees), end-diastolic pressure-
volume relationship (EDPVR) and the slope (stiffness constant),
and dp/dtmax and EDV relationship (dp/dtmax—EDV) were
calculated using iWorx systems software.
PICROSIRIUS RED (PSR) STAINING AND DETERMINATIONOF
COLLAGEN CONTENT
The paraformaldehyde fixed tissue was prepared using a tissue
processor and embedded in paraffin. The embedded tissue was
sectioned in 7μm thickness. The specimens were dewaxed, rehy-
drated, and stained with PSR to detect collagen fibers. The PSR
stained tissue specimens were photographed with a camera con-
nected to a polarized light microscope (ZEISS Axio Imager M1)
to detect birefringence of collagen fibers. Three fields were chosen
randomly from each heart sample. The images were quantified
by a semi-automated imaging analysis program (AxioVision). A
color threshold was defined in such a way to detect mature colla-
gen. The area of birefringence was normalized by the total area of
interest.
SAMPLE PREPARATIONAND EXPRESSIONOF MYOSIN HEAVY CHAIN
ISOFORM (MyHC)
MyHC isoforms were studied using SDS-PAGE as previously
described (Konhilas et al., 2006). Snap frozen ventricular tis-
sue was homogenized (Next Advance, Averill Park, NY) in 8M
Urea buffer (Urea 8M, Thiourea 2M, Tris 0.05M, DTT 75mM,
SDS 3%, Bromophenol blue 0.05%, pH 6.8). Samples were ana-
lyzed using SDS-PAGE (6% acrylamide, 37.5:1 cross-linked with
DATD). Gels were run in a Se600 Hoefer gel system at 4◦C at
a constant current of 16mA per gel. The gels were fixed and
stained using a Silver Stain Plus kit (BioRad 161-0449), dried,
and scanned (EPSON V750 PRO). The ratio of α-MyHC and
β-MyHC isoforms expressed was determined using densitome-
try (LabImage 1D L340 N3, Kaplean BioImaging System, Leipzig,
Germany). In order to confirm MyHC staining was within lin-
ear densitometric range, six or seven dilutions of each sample
were analyzed covering a 50–60 fold dilution range. Soleus mus-
cle which harbors β-MyHC was used as a β-MyHC standard.
From the linear relationships determined for each MyHC iso-
form, the relativeMyHC content of each isoformwas extrapolated
and compared to the densitometric values obtained.
WESTERN BLOT ANALYSIS
Frozen heart samples were prepared as detailed above and
run using 10% SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to a PVDF membrane. The trans-
ferred proteins were incubated with anti-phospholamban (PLN,
Thermo Scientific), anti-phospho-S16-phospholamban (p-PLN,
Upstate), sarcoplasmic reticulum Ca2+ ATPase (SERCA2A,
Thermo Scientific), total-cTnI (cTnI, AbCam), cTnI-ser23/24
(cTnI-S23/24, Cell Signaling) primary antibodies, then incubated
with horseradish-conjugated secondary antibodies. The enzy-
matic activity was detected using enhanced chemiluminescent
substrate kits. The intensity of the protein band was determined
using densitometry (LabImage 1D L340 N3, Kaplean BioImaging
System, Leipzig, Germany). In addition, prior to immunoblot-
ting, all membranes were stained with Ponceau S acid red and
quantified for total protein. Next, total protein measured by
coomassie blue and/or Ponceau S was compared to MHC expres-
sion for equal loading. All hearts of a given genotype at both 2
and 9 week timepoints were analyzed on a single immunoblot. All
immunoblot analysis was performed from the semi-quantitation
of individual blots and was not compared across blots accord-
ing to the guidelines set forth by the American Physiological
Society.
STATISTICAL ANALYSIS
Data are presented as Mean± SE. Mean differences among differ-
ent groups were examined using 2-way analysis of variance (SPSS,
IBM, version 19). Post-hoc tests were carried out using Bonferroni
t-tests. The logrank test was performed to compare the survival
distributions of WT TAC and FHC TAC. P-values < 0.05 were
considered to be significant.
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RESULTS
SURVIVAL
For the 9-week timepoint, a total of 58 mice (WT n = 29, FHC
n = 29) received either TAC (WT n = 18, FHC n = 18) or sham
procedure (WT n = 11, FHC n = 11). None of the sham ani-
mals died during the study period, however, TAC surgery resulted
in a statistically significant mortality rate where 13 of 36 (36%)
died. Gross anatomical exam of the expired mice revealed no
significant changes in cardiac-pulmonary system and no signifi-
cant anatomical changes in cardiac morphology. Of the mice that
underwent TAC surgery, those harboring the FHC mutant trans-
gene demonstrated greater mortality (8 of 18; 44%) during the
entirety of the study period, compared toWTmice (5 of 18; 28%).
A Kaplan–Meier curve summarizes these findings (Figure 1).
CARDIAC HYPERTROPHY AND ECHOCARDIOGRAPHY
We determined the impact of the FHC mutation and TAC on car-
diac hypertrophy through absolute and normalized heart weight.
The morphometric data from this study are summarized in
Figure 2 andTable 1. Consistent with previous data, at the 2-week
timepoint (Stauffer et al., 2006), the presence of the FHC muta-
tion in sham mice did not result in a measurable hypertrophy
by ventricular weight and ventricular weight normalized to body
weight (BW; Figure 2) or tibial length (Table 1). Following 2-
weeks of TAC, both WT and FHC mice developed significant
hypertrophy. Although FHC hearts following TAC were larger
by absolute or normalized heart mass, the proportional increase
(26.8 ± 5.7 vs. 18.7 ± 3.4% in FHC compared to WT hearts,
respectively) in cardiac mass was not statistically significant.
Previous work has shown that male FHC mice develop mea-
surable hypertrophy by 4 months of age (Vikstrom et al., 1996;
Olsson et al., 2001). Similarly, at the 9-week timepoint (4 months
FIGURE 1 | Kaplan–Meier survival analysis of WT and FHC mice after
TAC. Animals subjected to pressure overload died over the period of the
study. Mortality rate was greater in the mutant animals compared to WT
mice (p < 0.05).
of age), FHC-Sham hearts were larger than WT-Sham hearts
indicative of cardiac hypertrophy (Figure 2 and Table 1). In
response to 9 weeks of pressure overload by TAC, both WT
and FHC mice developed significant cardiac hypertrophy indi-
cated by an increase of 35.1 ± 6.2 and 30.6 ± 4.2% in ventricular
weight, respectively, over corresponding sham controls (Table 1).
Ventricular weight normalized to BW or TL showed a similar
increase. This robust hypertrophic response was observed despite
the use of a larger gauge (26 gauge) needle in order to induce a
more gradual pressure overload (see Methods). The extent of the
hypertrophic response, although proportionally greater in FHC
than in WT mice, again, was not statistically different between
the two groups.
To assess the impact of pressure overload by TAC on cardiac
function and in situ ventricular morphometry, high-resolution
2-deminsional echocardiography was performed on WT and
FHC-Sham and -TAC mice at each timepoint. Representative B-
mode images are illustrated in Figure 3. A functional decline as
a result of pressure overload by TAC was observed only in FHC
mice at the early (2 week) timepoint compared to all other groups
(Figure 4A). This functional deficit persisted in FHC mice fol-
lowing TAC at the late (9 week) timepoint only when compared
to WT-Sham mice; there was no longer a difference between
WT-TAC, FHC-Sham and FHC-TAC mice.
Although TAC induced cardiac hypertrophy in both WT
and FHC mice, the regional hypertrophic impact was different
between the 2 groups. The early (2 weeks post-TAC) response
of FHC hearts was a significant increase in left-ventricular inter-
nal dimension during diastole (LVIDd) compared to FHC-Sham
hearts whereas WT hearts responded to pressure overload with
a slight decrease that was not different from WT-Sham hearts
but reached significance when compared to FHC hearts following
FIGURE 2 | Summary of normalized cardiac mass in WT and FHC mice
with and without TAC. VW/BW at the 2- and 9-week timepoint was
determined by dividing ventricular mass (in mg) by body weight (in g). Data
presented as mean ± s.e.m. Experimental group numbers are indicated in
Table 1. (∗p < 0.05; §p < 0.05 from values obtained in WT-Sham).
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Table 1 | Body and cardiac mass.
WT-Sham (n = 10) WT-TAC (n = 12) FHC-Sham (n = 11) FHC-TAC (n = 10)
2 WEEKS POST-TAC
Morphometry
BW, g 23.4 ± 0.5 23.5 ± 0.7 23.4 ± 0.6 22.3 ± 0.5
Tibial length (mm) 18.4 ± 0.1 17.8 ± 0.2 18.5 ± 0.1 18.4± 0.1
VW (mg) 99.2 ± 1.7 117.7 ± 5.91 105.0 ± 3.03 133.1± 5.21,2,3
VW/TL (mg/mm) 5.4 ± 0.1 6.6 ± 0.21 5.7 ± 0.23 7.4 ± 0.31,2,3
9 WEEKS POST-TAC
Morphometry
BW, g 26.7 ± 0.9 27.7 ± 0.8 27.1 ± 1.0 27.3 ± 0.8
Tibial length (mm) 20.4 ± 0.2 20.1 ± 0.2 20.1 ± 0.2 20.3 ± 0.2
VW (mg) 98.8 ± 3.1 133.8 ± 5.91 126.4 ± 4.72,3 161.4± 6.81,2,3
VW/TL (mg/mm) 4.8 ± 0.1 6.5 ± 0.21 6.2 ± 0.22,3 7.2 ± 0.31,2,3
Summary of morphometric data from WT and FHC mice with and without TAC at 2 and 9 weeks post-TAC. VW/TL was determined by dividing cardiac mass (in mg)
by tibial length (in mm) values are presented as Mean ± s.e.m. 1p < 0.05 compared to corresponding sham controls. 2p < 0.05 compared to corresponding WT
animals. 3p < 0.05 compared to WT-TAC animals. BW, body weight; VW, ventricular weight. Numbers in parentheses indicate the number of animals per group.
FIGURE 3 | Representative 2-dimentional echo images showing left
ventricular chamber from the parasternal short-axis views. From
M-mode images, morphological measurements were made and
parameters were calculated as detailed in the Methods. Pressure
overload resulted in an increase in cardiac mass and wall thickness
without appreciable changes in chamber dimension. The extent of
increase in wall thickness is significantly greater in the FHC-TAC mice
compared to WT-TAC mice.
TAC (Figure 4B). By 9 weeks of TAC, the LVIDd was great-
est in both FHC and WT hearts compared to WT-Sham hearts.
Interestingly, FHC-Sham hearts developed a progressively larger
LVIDd, which was significantly greater thanWT-Sham hearts but
not compared to both TAC groups.
Despite a similar LVIDd between both sham groups
at the 2 week timepoint, FHC-Sham hearts showed an
increased thickness in the LV posterior wall during dias-
tole (LVPWTd) compared to WT-Sham hearts (Figure 4C).
However, TAC induced a significant thickening of the LVPW
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during diastole in both groups compared to WT-Shams but
similar to FHC-Shams. At 9 weeks post-TAC, LVPWTd con-
tinued to increase in FHC-TAC hearts to a thickness that
was significantly greater than all other groups. LVPWTd
measured in WT-TAC hearts remained significantly greater
than WT-Sham counterparts. Interestingly, the LVPWTd of
FHC-Sham hearts was no longer different than WT-Sham
hearts.
The consequence of these morphometric changes was an early
(2 weeks post-TAC) concentric hypertrophic response to TAC as
measured by the relative wall thickness (RWT) that persisted in
FHC-TAC hearts at 9 weeks post-TAC but progressed to eccen-
tric hypertrophy in the WT-TAC group at 9 weeks post-TAC
(Figure 4D). Unlike FHC hearts following TAC, FHC-Sham
hearts exhibited a progressively eccentric hypertrophic response.
LEFT-VENTRICULAR HEMODYNAMICS AND PRESSURE-VOLUME
LOOP ANALYSIS
Considering that the trajectory of ventricular remodeling was
impacted by the FHC transgene, we assessed in vivo LV
hemodynamics at 9 weeks post-TAC and the data are summarized
in Table 2. As mentioned above, the hearts of both WT and FHC
mice responded to the gradual pressure overload by TAC with
significant hypertrophy. As expected, TAC similarly increased sys-
tolic pressure in both WT and FHC mice by 43 ± 9.4 and 42 ±
9.4%, respectively. These data demonstrate that WT and FHC
FIGURE 4 | Echocardiographic parameters of ventricular function and
morphometry inWT and FHCmice with andwithout TAC. (A) Ejection
fraction (EF%); (B) LVIDd is LV internal diameter at end-diastole; (C) LVPWTd is
LV posterior wall thickness at end-diastole; (D) RWT is relative wall thickness
calculated as 2∗LVPWTd/LVIDd and represents a measure of LV eccentricity.
Data presented as mean± s.e.m. Experimental group numbers are as follows,
2 week group:WT-Sham, n = 9; WT-TAC, n = 8; FHC-Sham, n = 7; FHC-TAC,
n = 8. For 9 week group:WT-Sham, n = 9; WT-TAC, n = 10; FHC-Sham, n = 9;
FHC-TAC, n = 8. (∗p < 0.05 from values obtained in WT-Sham; ∗∗p < 0.05;
#p < 0.05 from values obtained in WT-Sham and FHC-Sham).
Table 2 | In vivo indexes of LV hemodynamics of WT and FHC mice with and without TAC at 9 weeks post-TAC.
Parameter WT-Sham (n = 9) WT-TAC (n = 10) FHC-Sham (n = 9) FHC-TAC (n = 8)
HR, bpm 425 ± 14 431 ± 11 428 ± 8 442 ± 8
ESP, mmHg 89 ± 3 127 ± 71 85 ± 5 121± 2a
dp/dtmax, mmHg/s 6363 ± 185 6670 ± 322 6738 ± 465 7104 ± 498
dp/dtmin, mmHg/s −5276 ± 258 −7670 ± 4451 −5252 ± 275 −6553 ± 545
Ees, mmHg/μl 2.2 ± 0.4 3.2 ± 0.31 3.0 ± 0.5 3.5 ± 0.2
PRSW, mmHg 53 ± 5 87 ± 101 59 ± 4 76 ± 8
tau (W), ms 8.2 ± 0.4 6.5 ± 0.21 7.6 ± 0.3 7.3 ± 0.4
Ea, mmHg/μl 3.8 ± 0.3 6.5 ± 1.01 3.7 ± 0.2 7.2 ± 0.41
Values are presented as Mean ± s.e.m. ap < 0.05 compared to corresponding sham controls. ESV, End-systolic volume; EDV, end-diastolic volume; ESP, end-systolic
pressure; EDP, end-diastolic pressure; Ees, end-systolic elastance; PRSW, preload-recruitable stroke work; Ea, arterial elastance.
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hearts were exposed to a similar magnitude of pressure overload.
Furthermore, TAC did not alter the maximum time derivative of
pressure development (dp/dtmax) but did significantly increase
the maximum time derivative of pressure decline (dp/dtmin) and
also shortened the time constant of LV pressure fall (tau) in WT
but not in FHC mice.
To determine load-independent parameters of ventricular
function (Burkhoff et al., 2005), pressure-volume loops were gen-
erated following IVC occlusion. A set of representative pressure-
volume loops following IVC occlusion from each experimental
group is shown in Figure 5 and summarized in Table 2. Although
TAC in WT mice did not elevate dp/dtmax, it significantly
enhanced end-systolic elastance (Ees, the slope of the end-systolic
pressure-volume relationship; ESPVR), relative to WT-Sham,
indicating an increase in contractility. This was also paralleled by
an increase in PRSW. Although these parameters were altered by
TAC inWTmice, we did not observe a similar change in pressure-
overloaded FHC mice. These data indicate that cardiac function
was increased in WT-TAC mice, whereas cardiac function was
unaltered in FHC-TAC mice, suggesting compensation of car-
diac function in WT mice compared to FHC mice in response to
TAC. In addition, pressure overload resulted in a similar increase
in effective arterial elastance in both groups indicating a similar
impact of TAC on arterial load.
CARDIAC REMODELING
In response to pathological stimuli including pressure overload,
the heart undergoes remodeling at the structural/ultrastructural,
cellular, and genetic level. Illustrative of this remodeling, TAC
hearts independent of transgene are enlarged and “stiff” fol-
lowing excision. Hallmarks of this remodeling include increased
deposition of collagen resulting in a “stiff” myocardium and a
recapitulation of the fetal gene program that includes elevated
expression of the β-isoform of myosin heavy chain (β-MyHC;
Perrino et al., 2006). Consistent with previous studies (Stauffer
et al., 2006), FHC mutant mice exhibited an increased deposition
of myocardial collagen (Figure 6). Although FHC hearts showed
significantly increased collagen content compared to WT hearts,
FIGURE 5 | Four representative LV pressure-volume loop tracings from
WT and FHC hearts with and without TAC at 9 weeks post-TAC.
there was not a measurable increase following TAC in either WT
or FHC hearts. Next, we examined whether the R403Q muta-
tion differentially impacts MyHC isoform shift following pressure
overload. FHC-TAC hearts were found to have a significantly
increased protein expression of β-MyHC at both 2 and 9 weeks
post-TAC (Figure 7). Two weeks of pressure overload did not
cause a heightened expression of β-MyHC in WT mice, however
at the 9 week timepoint WT-TAC mice have significantly higher
β-MyHC than sham counterparts (Figure 7).
ALTERED EXPRESSIONOF CA2+ HANDLING PROTEINS
In this study, we observed that TAC induced an increase in load-
dependent myocardial relaxation in WT hearts but not in FHC
hearts. Diastolic dysfunction is a hallmark of FHC and can result
from changes in myofilament function and/or Ca2+ handling
proteins. We hypothesized that the differential expression and
post-translational modification of Ca2+ handling proteins under-
lies these TAC-induced differences in cardiac function. Therefore,
we determined protein expression levels of SR Ca2+ ATPase
(2a) (SERCA2a) and PLN by Western blot analysis in WT and
FHC hearts with and without TAC at two different time points
(2 weeks and 9 weeks post-surgery) (Figure 8). Pressure over-
load decreased SERCA2a expression in WT-TAC mice as early as
2 weeks post-TAC and further decreased SERCA2a expression by
9 weeks post-TAC. No significant changes in SERCA2a expression
were found at either timepoint in FHC-TAC hearts.
PLN, a regulatory binding partner of SERCA2a, inhibits
SERCA2a Ca2+ uptake activity when bound. Pathological car-
diac stress, such as pressure overload, is known to stimulate
the β-adrenergic pathway and subsequently activate a down-
stream kinase, protein kinase A (PKA; Choi et al., 1997).
PKA targets PLN at serine 16 (PLN-S16), thus reducing PLN
affinity for SERCA, relieving inhibition of SERCA2a activ-
ity (Mattiazzi et al., 2005). In WT-TAC hearts, there was an
immediate and significant (2 weeks) down regulation of PLN
protein levels accompanied by increased PLN-S16 phosphory-
lation (p-PLN-S16; Figure 8). The net result was a significant
increase in the p-PLN-S16/PLN ratio. This became attenuated
FIGURE 6 | Collagen deposition in the hearts of WT and FHC mutant
mice after 9 weeks pressure overload. Left panel: Polarized microscopic
views of myocardial collagen. Right panel: Percentage of fibrosis.
Myocardial sections were stained with PSR. Thin collagen fibers have
green birefringence and thick collagen fibers have bright yellow/orange
birefringence under polarization light microscopy. Birefringence of collagen
fibers was quantified using a semi-automated imaging analysis program.
∗p < 0.05 compared to WT-sham.
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FIGURE 7 | Expression of β-MyHC protein in WT and FHC mice with and
without pressure overload. Top panel: Representative SDS-PAGE following
silver staining shows separation of α-MyHC and β-MyHC in dilutions of
2-week WT-TAC and FHC-TAC hearts. Bottom panel: The expression of
β-MyHC increases in response to pressure overload at the 2-week timepoint
only in the presence of the FHC mutation. Nine-week TAC causes a
significant increase in β-MyHC expression in both WT and FHC mice.
∗p < 0.01 vs. WT-sham and WT-TAC and HCM-sham; #p < 0.05 vs. WT-sham.
FIGURE 8 | Expression of Ca2+ handling proteins in WT and FHC
mice with and without TAC. Top panel: Ca2+ handling proteins,
SR Ca2+ -ATPase (2a) (SERCA2a), phospholamban (PLN), total cTnI,
and cTnI-S23/24 were assessed by immunoblot analysis. Bottom
panel: Bar graph representation of the relative impact of TAC in WT
and FHC hearts at 2 and 9 weeks post-TAC. In order to better
compare the impact of TAC, protein expression in each experimental
group subjected to TAC was compared to each respective sham
control (n = 4 in each group; ∗p < 0.05 from values obtained in
WT-Sham; #p < 0.05).
at 9 weeks post-TAC. On the other hand, early (2 week)
TAC in FHC-TAC hearts did not alter PLN expression or
altered the level of p-PLN-S16 (Figure 8). However, PLN lev-
els in FHC-TAC hearts fell below control levels at 9 weeks
post-TAC. Coupled with a slight decrease in total p-PLN-S16,
there was a significant increase in p-PLN-S16/PLN (9 weeks
post-TAC).
Desensitization following overstimulation of the β-adrenergic
pathway during pathological stress results in a decrease in
downstream adrenergic targeting (Choi et al., 1997). Indeed,
PKA-dependent phosphorylation of TnI at S22/23 (cTnI-S23/24)
is reduced in human and animal CHF (McConnell et al., 1997;
Kooij et al., 2010). In this study, we determined that the amount
of cTnI-S23/24 in WT hearts significantly decreased following
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9 weeks of TAC compared to 2 weeks. We found that the level of
cTnI-S23/24 was comparable, regardless of pressure overload in
FHC hearts.
DISCUSSION
In the face of pathological stress such as pressure overload, the
heart will adapt in order to meet the prevailing hemodynamic
load. Here, we show that cardiac adaptation to pressure over-
load is characterized by hypertrophy but, more importantly,
the pattern of hypertrophy is dependent upon the presence of
the mutant myosin FHC transgene. A less obvious conclusion
from this study, but perhaps more significant, implicates a more
general role for genetic background as a determinant of pheno-
typic outcome in response to pressure overload. Previous work
demonstrates that the type of LVH has a significant inheri-
table component (Barrick et al., 2007). Here, our findings of
pressure overload in FHC mice on the C57/B16 background par-
allel pressure overload in an alternative R403Q mouse model
(αMHC403/+) on the BS background but differ from pres-
sure overload in αMHC403/+ mice on the 129SvEv background
(Schmitt et al., 2003).
It must be noted that although both αMHC403/+ and FHC
mice were modeled after the R403Q mutation, the mutations
were introduced using distinct methodologies: the αMHC403/+
mouse model introduced the R403Q mutation into one allele
of the α-MHC by homologous recombination, while the FHC
mouse model used in this study expressed a mutant α-MHC
with expression driven by the rat α-MHC promoter result-
ing in 10–12% expression of the transgene (Vikstrom et al.,
1996). Furthermore, the FHC model in this study consists of
a deletion of 59 amino acids in the actin-binding site bridged
by the addition of 9 non-myosin amino acids. Because of
this unique genetic identity, this study is limited in attribut-
ing the phenotypic observations to the R403Q mutation
specifically.
Despite the genetic distinctions between the two R403Qmouse
models, both models exhibit many of the features seen in humans
with FHC, including LV and right ventricular (RV) hypertro-
phy, cellular disarray, and fibrosis (Geisterfer-Lowrance et al.,
1996; Vikstrom et al., 1996). This latter finding holds a partic-
ular clinical relevance considering that these two R403Q mouse
lines are distinct, pathological FHC models and represent the
genetic and phenotypic heterogeneity in the human clinical pop-
ulation. Therefore, these models can be used to elucidate cellular
mechanisms leading to the clinical phenotype independent of
genotype. Moreover, a recent statement by the National Heart,
Lung, and Blood Institute states that, despite a poor mechanistic
understanding of this clinical heterogeneity, the overarching goal
is to identify novel strategies at preventing the clinical phenotype
(Force et al., 2010). It further suggests that success of this goal will
largely depend on the delineation of cellular signaling pathways
that can modify the FHC phenotype, rather than identification
of the specific mutation. Clearly, these two models represent
distinct courses of cardiac pathophysiology and underscore the
significance of identifying unique modifying factors.
In an attempt to model the clinical development of arterial
hypertension in mice, we induced pressure overload by TAC in
developing (2-month-old) mice using a less severe aortic constric-
tion (see Methods). This study was also designed to potentially
reveal key factors of the pathological trajectory by examining an
early (2 weeks post-TAC) and a transitional, pre-CHF (9 weeks
post-TAC) timepoint. Although the initial hemodynamic load
imparted was presumably lower, both WT and FHC mice show
a hypertrophic response measured at 2 and 9 weeks post-TAC.
More importantly, the pathological trajectory of the hypertrophic
response is very different. FHC-TAC hearts following 2 weeks of
TAC are larger than all other groups. However, WT-TAC hearts
continue to increase in mass whereas FHC-TAC hearts do not.
The suggestion is that FHC hearts reach a hypertrophic “limit”
early in the pathological response to TAC compared to WT
hearts. Incidentally, FHC-Sham hearts show significant hypertro-
phy at the 9 weeks (4 months) timepoint consistent with previous
findings (Vikstrom et al., 1996; Stauffer et al., 2006).
Along with the increasing cardiac mass, WT-TAC hearts pro-
gressively dilate without a change in posterior wall thickness
(LVPWd). FHC-TAC hearts, on the other hand, do not dilate
but show increased LVPWd thickness. The net result of these
morphological changes is an early elevation of the RWT in WT-
TAC and FHC-TAC. Once again, the pathological course depends
on the presence of the R403Q transgene; at 9 weeks post-TAC,
RWT decreases in WT-TAC hearts but continues to increase in
FHC-TAC hearts.
In light of these data, the temporal patterning of ventricular
structure and geometry in response to pressure overload is depen-
dent on genotype and may lend prognostic value in stratifying
patients based on cardiovascular risk as detailed below. Clinical
evaluation of hypertensive patients indicates that total mortal-
ity correlates with the type of ventricular hypertrophy, or more
specifically, ventricular remodeling (Koren et al., 1991; Ganau
et al., 1992; Gaasch and Zile, 2011). In this study, WT-TAC hearts
initially (2 weeks post-TAC) display an elevated RWT with lim-
ited hypertrophy andwithout an increase in chamber dimensions,
termed concentric remodeling (Koren et al., 1991). Although clin-
ically correlated with adverse outcomes, this type of concentric
ventricular remodeling is associated with reduced mortality com-
pared to remodeling characterized by an elevated RWT coupled
with increased cardiac mass and chamber dimensions (concentric
hypertrophy) as observed early (2 weeks post-TAC) in FHC-TAC
hearts (Koren et al., 1991; Ganau et al., 1992).
Subsequently, WT-TAC hearts follow a pathological pat-
tern of increasing cardiac mass and chamber dimensions
(dilation) defined as eccentric hypertrophy, whereas FHC-TAC
hearts maintain chamber geometry consistent with worsen-
ing concentric hypertrophy. Again, patients with established
concentric hypertrophy due to hypertension have the most
severe clinical outcomes (Gaasch and Zile, 2011). Moreover,
the increased RWT often found in individuals with valvu-
lar heart disease and/or aortic stenosis is a strong indica-
tor for poor prognosis and is an independent risk factor
for cardiovascular mortality and morbidity (Levy et al., 1990;
Orsinelli et al., 1993). In patients with FHC, ventricular wall
thickness is directly proportional to the clinical severity of
the disease and the risk of sudden cardiac death (Spirito
et al., 2000; Maron, 2002). Incidentally, LVPWd continues to
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thicken in FHC-TAC hearts consistent with worsening concentric
hypertrophy.
Based upon hemodynamic analysis, eccentric hypertrophy in
9-week WT-TAC hearts is accompanied by elevated Ees and
PRSW, indications that these hearts are in a compensatory state
of cardiac hypertrophy with elevated cardiac function (Gaasch,
1979; Khouri et al., 2010). Likewise, the preserved ratio of Ea to
Ees, an indicator of ventricular and vascular coupling, in the pres-
ence of an increased Ea, a measure of afterload, further supports
this contention (Yang et al., 1999; Kass, 2002). UnlikeWT hearts,
cardiac function of FHC hearts following TAC demonstrates no
functional increase when compared to FHC-Sham hearts, sug-
gesting that FHC hearts respond and compensate to pressure
overload differently than WT hearts. This may be due to a com-
pensatory or pathological “limit” of FHC hearts that is different
than the level attained by WT mice. Furthermore, it is conceiv-
able that because FHC-Sham hearts demonstrate a priori elevated
systolic parameters [Table 2 and Georgakopoulos et al. (1999)]
ventricular remodeling is markedly dissimilar thanWT-TACmice
and may underlie the increased mortality in FHC mice. Another
finding in the present study is that gradual pressure overload
increases the rate of maximal LV pressure decline (dp/dtmin)
and shortens the time constant of the pressure fall (tau) in
WT animals, an indication of the enhanced load dependence
of myocardial relaxation (Cohn et al., 1972; Leite-Moreira and
Gillebert, 1994). These responses are blunted in the FHC mutant
mice. Although EDPVR, a measure of myocardial stiffness, is not
different between WT and FHC mice, these data suggest a funda-
mental difference in ventricular properties related to relaxation.
Taken together, functional evaluation and morphological assess-
ment suggest that FHC hearts possess a limited ability to undergo
compensatory hypertrophy in response to pressure overload and
illustrate a different hypertrophic pattern relative to WT animals.
Considering the differential impact of TAC on morphomet-
ric and functional adaptation in WT compared to FHC mice, we
shifted our focus to the cellular processes that may underlie these
differences. Not surprisingly, we reveal that the FHC transgene
induces a unique pattern of cellular adaptation. Using β-MyHC as
a measure of pathological progression, FHC hearts show an early
elevation (2 weeks) of β-MyHC compared to all other groups.
WT hearts post-TAC demonstrate the typical increased expres-
sion of β-MyHC but until a later timepoint. This further indicates
that FHC hearts are at a distinct pathological state at the outset.
Taking into account the differences in both contractile and relax-
ation parameters, we targeted the temporal expression pattern of
intracellular Ca2+-handling proteins. In addition, we evaluated
the response to TAC by comparing the relative change of protein
levels to the appropriate controls as opposed to comparing abso-
lute protein levels across all experimental groups. Since the FHC
transgene initiates a unique genetic program very early (Stauffer
et al., 2006; Luczak et al., 2011), we reasoned that this analytical
approach would be representative of adaptive potential or, more
appropriately, capacity. Thus, we can directly test whether FHC
hearts have limited cellular adaptive capacity at the cellular much
like at the morphological and functional level detailed above.
Using this strategy, we illustrate a significant decrease in SERCA2a
protein levels 2 weeks post-TAC, consistent with previous models
of pressure overload (Kranias and Hajjar, 2012), in WT hearts
only. Furthermore, SERCA2a in WT hearts continues to fall with
sustained pressure overload (9 weeks post-TAC) to levels below
that of the 2-week post-TAC group compared to respective WT
controls. A drop in SERCA2a protein is not seen in FHC hearts at
either timepoint, again, suggesting an inability to further adapt.
PLN acts as a negative regulator of SERCA2a activity and phos-
phorylation of PLN relieves this inhibitory effect on SERCA2a
(Kranias and Hajjar, 2012). Many studies have subsequently
established a critical role for PLN expression and phosphorylation
as a modulator of Ca2+ flux and myocyte contractility in rodent
models of CHF (Kranias and Hajjar, 2012). In this study, the early
response to TAC inWT hearts is to increase PLN phosphorylation
at the PKA site, Ser16 (McTiernan et al., 1999), relieving the inhi-
bition on SERCA2a and increasing Ca2+ uptake by the SR. This
elevation of PLN-S16 phosphorylation in WT hearts becomes
attenuated to control levels at 9 weeks post-TAC. In contrast, FHC
hearts show no change in PLN protein or phosphorylation levels
early but demonstrate a latent increase in PLN-S16 phosphoryla-
tion. It must be noted that this increase in PLN phosphorylation
in partially driven by a significant decrease in PLN expression that
occurs with increasing CHF progression (McTiernan et al., 1999).
CONCLUDING REMARKS
In conclusion, data from the present study demonstrates that the
temporal andmorphological pattern of ventricular remodeling in
response to pressure overload depends not only on the presence
of a mutant myosin (R403Q) transgene but also on genetic back-
ground. The differential ventricular remodeling is manifest as
premature death, a more severe hypertrophy, altered load depen-
dence of myocardial relaxation, and aberrant cellular adaption in
FHC mice. Although the underlying mechanisms inducing this
aberrant remodeling in the FHC mice is not known, it is most
likely the combinatorial result of the pre-existing disease and the
ensuing genetic and molecular signaling cascade. Given that con-
centric hypertrophy and diastolic dysfunction are central features
of FHC and important to pathophysiology of heart failure, our
findings may reflect early pathogenesis that underlies the FHC
disease progression in the setting of co-existing pressure overload.
Perhaps more importantly is that this study de-emphasizes the
relative importance of defining the specific genotype as it relates
to the pathophysiology and highlights the significance of iden-
tifying the mechanisms leading to the cellular phenotype. This
latter notion is not only in line with the recent underpinnings of
a statement by the NHLBI (Force et al., 2010) but also may lead
to potential therapeutic targets for the prevention and treatment
of FHC.
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